CHUGAI SEIYAKU KABUSHIKI KAISHA

ACTEMRA

PHARMACEUTICAL PREPARATIONS, NAMELY, ANTI-INTERLEUKIN-6 (IL-6) RECEPTOR MONOCLONAL ANTIBODY FOR THE TREATMENT OF DISEASE CAUSED BY IL-6 PRODUCTION;

ALAKANSA

pharmaceutical preparation, namely, an anti-cancer drug;The wording ALAKANSA has no meaning in a foreign language.;

ALECEMIO

pharmaceutical preparation, namely, an anti-cancer drug;The wording ALECEMIO has no meaning in a foreign language.;

ALECENSA

pharmaceutical preparation, namely, an anti-cancer drug;The wording ALECENSA has no meaning in a foreign language.;

ALECENSA

Providing educational classes, seminars, workshops, symposiums and conferences and training services in the medical field;The mark consists of three parallel lines bent at an angle in red, orange and yellow. Next to the lines is the word ALECENSA in red stylized font.;Pharmaceutical oncology preparations;The color(s) red, orange, and yellow is/are claimed as a feature of the mark.;The wording ALECENSAhas no meaning in a foreign language.;Providing medical information on pharmaceuticals and other medical information;

CARFENIL

PHARMACEUTICAL PREPARATIONS, NAMELY, DRUGS FOR USE IN THE PREVENTION AND TREATMENT OF RHEUMATISM, NEPHRITIS, PSORIASIS, AND DISEASES CAUSED BY THE AUTOIMMUNE SYSTEM; AND IMMUNOMODULATER;

DUAL-IG

Pharmaceutical preparations for human use, namely, pharmaceutical antibodies or its fragments or its derivatives, cells and genes that produce antibodies, fragments of antibodies or derivatives of antibodies for use in the treatment or prevention of infectious and parasitic diseases, cancer, blood and blood-forming organs diseases and disorders involving the immune mechanism, endocrine, nutritional and metabolic diseases, mental and behavioral disorders, diseases of the nervous system, diseases of the eye and adnexa, diseases of the ear and mastoid process, diseases of the circulatory system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin and subcutaneous tissue, diseases of the musculoskeletal system and connective tissue, diseases of the genitourinary system, pregnancy, childbirth and the puerperium, and congenital malformations, deformations and chromosomal abnormalities, for medical and pharmaceutical use;Granting of licenses to others for the use of industrial property rights and copyright;Pharmaceutical research and development services and providing information about medical and scientific research in the field of pharmaceuticals;

EMRESEB

Pharmaceutical preparations for the treatment of neuromyelitis optica;

ENSPRYNG

Pharmaceutical oncology and neuroendocrine hormone preparations;

ENSPRYNG

Pharmaceutical preparations for the treatment of neuromyelitis optica spectrum disorder;INSPIRING;

ENSPRYNG

Pharmaceutical preparations for the treatment of neuromyelitis optica spectrum disorder;

HEMCIBRA

Pharmaceutical preparations for the treatment of hemophilia A;

HEMLEKA

pharmaceutical preparations for the treatment of Hemophilia A;

HEMLIBRA

pharmaceutical preparations for the treatment of Hemophilia A;

HEMLIBRA

Providing educational classes, seminars, workshops, symposiums and conferences and training services in the medical field;The mark consists of the word HEMLIBRA with three curved stacked lines above the letter H.;Color is not claimed as a feature of the mark.;Providing medical information on pharmaceuticals and other medical information;

IKOREL

Pharmaceutical products; namely, a cardio-vascular preparation;

IKOREL

Pharmaceutical preparations for the treatment of cardiovascular and cerebrovascular disease;The word(s) IKOREL has no meaning in a foreign language.;

K

pharmaceutical preparations; namely, a cardio-vascular preparation;

K

Pharmaceutical preparations; namely, a cardiovascular preparation;K O;

K

The mark consists of the stylized letters KO where the letter K is combined with a circle design.;In the statement, Column 1, line 1, CHUGAI SEIYAKU KABUSHI KAISHA should be deleted, and CHUGAI SEIYAKU KABUSHIKI KAISHA should be inserted.;Pharmaceutical preparations for the treatment of cardiovascular disease;Color is not claimed as a feature of the mark.;